Health Insurance · NYSE: HUM
Humana earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 10 Feb 2027
Latest: Q3 2026
Humana's Bonus Year 2028 Star Ratings came in well above its top-quartile goal, and early 2027 enrollment signals are strong as CenterWell Primary Care and Medicaid keep expanding.
Humana's individual Medicare Advantage, stand-alone Part D, Medicaid and CenterWell businesses all grew this year. CenterWell Primary Care added 146,800 patients, or 30%, partly through the MaxHealth acquisition. Medicaid grew through new integrated dual-eligible programs in Michigan, Illinois and South Carolina. Pharmacy grew through Humana's own members and more non-Humana clients. A new BlackRock joint venture replaced the Welsh, Carson, Anderson & Stowe joint ventures that fund Primary Care clinics.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $29.2B * |
| Q1 2025 | $32.1B |
| Q2 2025 | $32.4B |
| Q3 2025 | $32.6B |
| Q4 2025 | $32.5B * |
| Q1 2026 | $39.6B |
| Q2 2026 | $40.9B |
| Q3 2026 | $41.2B |
Data
| Q1 2025 | $10.30 |
| Q2 2025 | $4.51 |
| Q3 2025 | $1.62 |
| Q1 2026 | $9.83 |
| Q2 2026 | $5.73 |
| Q3 2026 | $1.33 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | -1.9% |
| Q1 2025 | 6.3% |
| Q2 2025 | 3.4% |
| Q3 2025 | 1.2% |
| Q4 2025 | -2.5% |
| Q1 2026 | 4.4% |
| Q2 2026 | 3.3% |
| Q3 2026 | 0.2% |
Data
| Q4 2024 | -$682.0M |
| Q1 2025 | $236.0M |
| Q2 2025 | $1.2B |
| Q3 2025 | $836.0M |
| Q4 2025 | -$1.9B |
| Q1 2026 | $1.1B |
| Q2 2026 | $1.8B |
| Q3 2026 | $2.0B |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.2Bd | $32.1B | $32.4B | $32.6B | $32.5Bd | $39.6B | $40.9B | $41.2B |
| Operating income | -$543.0Md | $2.0B | $1.1B | $400.0M | -$808.0Md | $1.8B | $1.4B | $75.0M |
| Operating margin | -1.9% | 6.3% | 3.4% | 1.2% | -2.5% | 4.4% | 3.3% | 0.2% |
| Net income | -$693.0Md | $1.2B | $545.0M | $195.0M | -$796.0Md | $1.2B | $694.0M | $162.0M |
| Diluted EPS | — | $10.30 | $4.51 | $1.62 | — | $9.83 | $5.73 | $1.33 |
| Operating cash flow | -$528.0Md | $331.0M | $1.3Bd | $971.0Md | -$1.7Bd | $1.3B | $2.0Bd | $2.2Bd |
| Capital expenditure | $154.0Md | $95.0M | $114.0Md | $135.0Md | $202.0Md | $121.0M | $132.0Md | $137.0Md |
| Free cash flow | -$682.0M | $236.0M | $1.2B | $836.0M | -$1.9B | $1.1B | $1.8B | $2.0B |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 6 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 29 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 29 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 19 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 5 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 30 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 30 Apr 202510-Q for the period ended 31 Mar 2025SEC ↗
- 20 Feb 202510-K for the period ended 31 Dec 2024SEC ↗